Prashant Pandey
Overview
Explore the profile of Prashant Pandey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yadav S, Arya D, Kanaujiya S, Kumar S, Kushwaha D, Kumar A, et al.
ACS Appl Bio Mater
. 2025 Mar;
PMID: 40074674
Multidrug resistance (MDR) infectious wounds are a major concern due to drug resistance, leading to increased patient morbidity. Lichenysin (LCN), a lipopeptide and biosurfactant obtained from certain strains of ,...
2.
Pandey P, Kumari S, Agarwal G, Goel S, Setya D, Mandal S, et al.
Transfus Clin Biol
. 2025 Feb;
PMID: 39923889
Background And Objectives: Red cell transfusion is the mainstay of therapy for anemia and it is important to transfuse adequate dosage of red cells to maintain tissue oxygen demands. Additionally,...
3.
Arya D, Pandey P, Kumar A, Chidambaram K, Al Fatease A, Pandey G, et al.
J Liposome Res
. 2025 Feb;
:1-15.
PMID: 39895032
Personalized treatment strategies have greatly improved the efficacy of anticancer drugs. Nanocarriers, especially liposomes, function as excellent platform for the delivery of both hydrophilic and hydrophobic agents. iRGD is a...
4.
Pandey P, Arya D, Kumar A, Kaushik A, Mishra Y, Rajinikanth P
J Mater Chem B
. 2025 Jan;
13(8):2682-2694.
PMID: 39841132
This research demonstrates the design and development of a novel dual-targeting, pH-sensitive liposomal (pSL) formulation of 5-Fluorouracil (5-FU), , (5-FU-iRGD-FA-pSL) to manage breast cancer (BC). The motivation to explore this...
5.
Tripathi D, Gupta T, Rai A, Pandey P
Anticancer Agents Med Chem
. 2025 Jan;
PMID: 39773055
Oral cancer, currently ranked 16th among the most prevalent malignancies worldwide according to GLOBOCAN, presents significant challenges to global oral health. Conventional treatment modalities such as surgery, radiation, and chemotherapy...
6.
Pandey P, Pande A, Marik A, Devra A, Sinha V, Bhatt A, et al.
Transpl Immunol
. 2024 Dec;
88:102164.
PMID: 39716647
Aim: Detection of anti-HLA antibodies is crucial for pre-transplant histocompatibility testing, donor selection, and graft survival. The aim of this study was to evaluate the spectrum of anti-HLA antibodies among...
7.
Tripathi D, Rathour K, Pandey P, Kumar Tiwari R, Rai A
ADMET DMPK
. 2024 Dec;
12(6):881-901.
PMID: 39713257
Background And Purpose: The study explores basil seed mucilage as a bioadhesive carrier for naproxen sodium, demonstrating its ability to enhance solubility when administered rectally. The mucilage, derived from seeds,...
8.
Pandey P, Marik A, Tiwari A, Das S, Shastry S, Kute V, et al.
J Clin Apher
. 2024 Dec;
39(6):e70003.
PMID: 39711039
ABO-incompatible transplantations are increasingly gaining relevance with advancements in therapeutic modalities, thus allowing patients to receive timely solid organ transplants. Therapeutic apheresis (TA) procedures remain instrumental as a preconditioning measure...
9.
Tripathi D, Gupta T, Pandey P
Mol Biol Rep
. 2024 Oct;
51(1):1050.
PMID: 39395120
Radiotherapy is a cornerstone in the treatment of solid tumors, with extensive Phase III trials confirming its effectiveness. As advancements in treatment technologies and our understanding of tumor resistance mechanisms...
10.
Arya D, Deshpande H, Kumar A, Chidambaram K, Pandey P, Anjum S, et al.
Pharmaceutics
. 2024 Sep;
16(9).
PMID: 39339166
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer metastasis remains the primary cause of mortality among women globally. Targeted therapies have revolutionized treatment efficacy, with Trastuzumab (Trast), a monoclonal antibody,...